Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Pharmaceuticals Inc.

Division of Mylan NV

Latest From Mylan Pharmaceuticals Inc.

US Launch Of Sensipar Generics May Await Patent Case Even After FDA Approval

Aurobindo remains embroiled in litigation with Amgen on a Sensipar formulation patent, while Cipla settled ahead of  bench trial. Generic firms won approval of cinacalcet generics after two federal courts denied Amgen's emergency request for an injunction in dispute with FDA over pediatric exclusivity.

Generic Drugs Pediatrics

Mohawk Tribe Is Not Immune To IPR (And Allergan Really Owns Restasis Patents Anyway) PTAB Decrees

Allergan's novel tactic to derail inter partes review of Restasis patents ends for now as Patent Trial and Appeal Board denies Tribe's request to terminate proceeding; Board sets June 6 deadline for final written decision on IPR petition.

Policy Intellectual Property

Will FTC Shakeup Impact Pharma?

With full slate of new commissioners FTC may expand focus to FDA regulatory issues; Commission has four cases against pharma companies in federal court and is fighting challenges to its authority to bring pay-for-delay suits.
FDA Intellectual Property

Namenda XR Generics Coming Soon? US Court Rulings Clear Path For Multiple Launches

Seven companies hold final ANDA approval for Alzheimer's drug, but Allergan still has chance to block them as it seeks rehearing of appeals court's patent decision. Meanwhile, Amneal might block other generics if it can get an appeals court to grant it the 180-day marketing exclusivity for memantine extended-release it says that FDA unfairly denied it.

Generic Drugs Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mylan NV
  • Senior Management
  • Hal Korman, Pres.
  • Contact Info
  • Mylan Pharmaceuticals Inc.
    Phone: (304) 599-2595
    781 Chestnut Ridge Rd.
    P.O. Box 4310 Morgantown, WV 26505